Literature DB >> 4009236

Cholecystokinin-induced excitation in the substantia nigra: evidence for peripheral and central components.

D W Hommer, M Palkovits, J N Crawley, S M Paul, L R Skirboll.   

Abstract

Cholecystokinin (CCK), one of the most common brain peptides, coexists with dopamine (DA) in neurons of the medial substantia nigra (SN). CCK has been shown to excite these neurons following either direct iontophoretic or systemic administration suggesting that peripherally administered CCK may cross the blood brain barrier to act directly on nigral DA cells. However, biochemical evidence suggests that CCK does not cross the blood brain barrier, and several studies have shown that the behavioral and the satiety-inducing effects of peripherally administered CCK are abolished by vagotomy. In order to test for vagal mediation of the nigral response to systemically administered CCK, we examined the effects of a series of lesions to the vagal pathways on CCK-induced excitation in the SN. Neither acute thoracic nor chronic subdiaphragmatic vagotomies had any effect on the excitatory response of nigral DA neurons to systemically administered CCK. High cervical spinal cord transections were similarly without effect. In contrast, lesions of either vagal fibers in the medulla or of the efferent pathways from the nucleus tractus solitarii, the primary sensory nucleus of the vagus, produced significant attenuations of the nigral effects of systemically administered CCK. However, neither lesion blocked effects of CCK completely. We suggest that peripherally administered CCK has two components to its excitatory action in the SN; a component probably mediated through CCK receptors in the nucleus tractus solitarii and a direct action on DA neurons.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009236      PMCID: PMC6565261     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  8 in total

1.  Effects of cholecystokinin-8s in the nucleus tractus solitarius of vagally deafferented rats.

Authors:  V Baptista; K N Browning; R A Travagli
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-11-22       Impact factor: 3.619

2.  Changes in GABA content and turnover in discrete regions of rat brain after systemic administration of caerulein.

Authors:  K Nakamura; T Matsumoto; M Hirano; H Uchimura
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  A critical re-evaluation of the specificity of action of perivagal capsaicin.

Authors:  K N Browning; T Babic; G M Holmes; E Swartz; R A Travagli
Journal:  J Physiol       Date:  2013-01-07       Impact factor: 5.182

4.  Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.

Authors:  J Harro; M Põld; E Vasar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

5.  Cholecystokinin octapeptide increases spontaneous glutamatergic synaptic transmission to neurons of the nucleus tractus solitarius centralis.

Authors:  V Baptista; Z L Zheng; F H Coleman; R C Rogers; R A Travagli
Journal:  J Neurophysiol       Date:  2005-08-10       Impact factor: 2.714

Review 6.  Satiety Associated with Calorie Restriction and Time-Restricted Feeding: Central Neuroendocrine Integration.

Authors:  Debra K M Tacad; Ashley P Tovar; Christine E Richardson; William F Horn; Nancy L Keim; Giri P Krishnan; Sridevi Krishnan
Journal:  Adv Nutr       Date:  2022-06-01       Impact factor: 11.567

7.  Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.

Authors:  E Vasar; J Harro; A Lang; A Pôld; A Soosaar
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Effects of brain stem cholecystokinin-8s on gastric tone and esophageal-gastric reflex.

Authors:  Gregory M Holmes; Melissa Tong; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-08       Impact factor: 4.052

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.